胰激肽原酶联合缬沙坦治疗老年2型糖尿病肾病的临床观察

Clinical observation on effect of kallikrein united valsartan in the treatment of the elder with type 2 diabetic nephropathy

目的观察胰激肽原酶联合缬沙坦对2型糖尿病肾病(DN)尿白蛋白排泄率(UAER)的影响。方法50例早期DN(UAER20～200μg/min)患者随机分成两组,对照组(缬沙坦组)24例,观察组(胰激肽原酶加缬沙坦)26例,观察12w,比较治疗前后患者UAER、空腹血糖、HbA1c、血压、血肌酐等指标。结果治疗后两组UAER均较治疗前有显著下降(P<0.01),观察组较对照组降低明显(P<0.05)。结论缬沙坦可减少DN尿蛋白排出,与胰激肽原酶联用疗效更佳。

Objective To observe the effect of kallikrein united valsartan on urinary albumin excretion rate (UAER) of the patients with diabetic nephropathy (DN). Methods 50 cases of early DN (UAER 20～200 μg/min) were randomly divided into control group (n=24, only given valsartan) and treatment group (n=26, given kallikrein united valsartan). The UAER, fasting blood glucose (FBG), glycosylated hemoglobin (HbAlc), blood pressure and serum creatinine (SCr ) were determined before and 12 weeks after treatment.Results UAER reduced significantly after treatment in the two groups (P< 0.01), and UAER in treatment group decreased significantly than that in control groups (P< 0.05).Conclusions Angiotensin II receptor blocker valsartan could decrease UAER, and united kallikrein has better therapeutic effects on DN.